Fifth, exploring combination strategies involving statins and non-statin agents (e.g., PCSK9 inhibitors, ezetimibe) in statin-resistant individuals may help optimize outcomes in precision-guided, post-stroke lipid management. The gene discussed is PCSK9; the disease is stroke disorder.